

- 9 Szafranski W, Cukier A, Ramirez A, *et al.* Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. *Eur Respir J* 2003; 21: 74–81.
- 10 Calverley P, Pauwels R, Vestbo J, *et al.* Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. *Lancet* 2003; 361: 449–456.
- 11 Brusasco V, Hodder R, Miravittles M, *et al.* Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. *Thorax* 2003; 58: 399–404.
- 12 Vincken W, van Noord JA, Greefhorst APM, *et al.* Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. *Eur Respir J* 2002; 19: 209–216.
- 13 Casaburi R, Mahler DA, Jones PW, *et al.* A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. *Eur Respir J* 2002; 19: 217–224.
- 14 Burge PS, Calverley PMA, Jones PW, *et al.* Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ*, 320: 1297–1303.
- 15 Pauwels R, Lofdahl CG, Laitinen LA, *et al.* Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. *N Engl J Med* 1999; 340: 1948–1953.
- 16 Vestbo J, Sorensen T, Lange P, *et al.* Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. *Lancet* 1999; 353: 1819–1823.
- 17 Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med* 2000; 343: 1902–1909.
- 18 Niewoehner DE, Erbland ML, Deupree RH, *et al.* Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. *N Engl J Med* 1999; 340: 1941–1947.
- 19 Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999; 354: 456–460.
- 20 Collet JP, Shapiro S, Ernst P, *et al.* Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1997; 156: 1719–1724.
- 21 Orcel B, Delclaux B, Baud M, Derenne Ph. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. *Eur Respir J* 1994; 7: 446–452.
- 22 Solèr M, Mütterlein R, Cozma G. Prevention of acute exacerbations in chronic bronchitis and COPD with OM-85: a double-blind, placebo-controlled trial. *ATS International Conference Proceedings* 2004, A766.
- 23 Lusuardi M, Capelli A, Donner CF. Lung immune defences after stimulation of gut-associated lymphoid tissue with OM-85 BV: a double-blind study in patients with chronic bronchitis. *Eur Respir Rev* 1996; 6: 182–185.
- 24 Emmerich B, Emslander HP, Pachmann K, *et al.* Local immunity in patients with chronic bronchitis and the effects of a bacterial extract, Bronco-AvxomR, on T-lymphocytes, macrophages, gamma-interferon and secretory immunoglobulin A in bronchoalveolar lavage fluid and other variables. *Respiration* 1990; 57: 90–99.
- 25 Quezada A, Maggi L, Perez MA, Rodriguez J. Effect of bacterial antigen lysate on IgG and IgA levels in children with recurrent infections and hypogammaglobulinaemia. *J Inv Allergol Clin Immunol* 1999; 9: 178–182.
- 26 Grove AK, Bergemann R, Keller R. Preventive treatment of chronic bronchitis: a cost-effectiveness analysis for an immunoactive bacterial extract in Switzerland. *BMJ Economics* 1996; 10: 1–14.
- 27 Collet JP, Ducruet T, Haider S, *et al.* Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patient with chronic obstructive pulmonary disease. *Can Respir J* 2001; 8: 27–33.
- 28 Steurer-Stey C, Bachmann LM, Steurer J, Tramèr MR. Oral purified bacterial extracts in chronic bronchitis and COPD: systematic review. *Chest* 2004; 126: 1645–1655.

DOI: 10.1183/09059180.05.00009508

AUTHOR CORRECTION

“Treatment of stable COPD: antioxidants”. W. MacNee. *Eur Respir Rev* 2005; 14: 94, 12–22.

Figure 1. *Eur Respir Review* 14: 94 p. 13. This figure has been redrawn from Bowler RP, Barnes PJ, and Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2004; 1: 255–277 with permission. Copyright Taylor & Francis Group, 2005.

Figure 2. *Eur Respir Review* 14: 94 p. 13. This figure has been redrawn from Bowler RP, Barnes PJ, and Crapo JD. The role of oxidative stress in chronic obstructive pulmonary disease. *COPD: Journal of Chronic Obstructive Pulmonary Disease*. 2004; 1: 255–277 with permission. Copyright Taylor & Francis Group, 2005.